Abstract: A server of a crop growth stage determination system includes a processor. The processor inputs first images obtained by image capturing crops in a manner such that crop shapes are extractable. The Processor inputs growth stages each indicating a level of physiological growth of the crops for each of the first images. The processor constructs a learned model by performing deep learning to associate images of the crops and growth stages of the crops based on the input first images and the input growth stage. The processor inputs a second image obtained by image capturing crops a growth stage of which is unknown, in a manner such that crop-shapes are extractable. The processor determines the growth stage for the input second image based on the learned model. The processor outputs the determined growth stage.

Abstract: A server of a crop growth stage determination system includes a processor. The processor inputs first images obtained by image capturing crops in a manner such that crop shapes are extractable. The Processor inputs growth stages each indicating a level of physiological growth of the crops for each of the first images. The processor constructs a learned model by performing deep learning to associate images of the crops and growth stages of the crops based on the input first images and the input growth stage. The processor inputs a second image obtained by image capturing crops a growth stage of which is unknown, in a manner such that crop-shapes are extractable. The processor determines the growth stage for the input second image based on the learned model. The processor outputs the determined growth stage.

Abstract: Compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: ##STR1## (where R is a group --NHCHR.sub.1 R.sub.2, --N(CHR.sub.1 R.sub.2).sub.2, --N(CHR.sub.1 R.sub.2)CHR.sub.3 R.sub.4, --N.sup.+ (CHR.sub.1 R.sub.2).sub.3, --N.sup.+ (CHR.sub.1 R.sub.2).sub.2 CHR.sub.3 R.sub.4 or --N.sup.+ (CHR.sub.1 R.sub.2)(CHR.sub.3 R.sub.4)CHR.sub.5 R.sub.6 (where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6, which may be the same or different, are each a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group, or an alkyl, alkenyl, aryl or aralkyl group which is substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkylacyloxy group, a lower alkylacyl group, a lower alkoxycarbonyl group, a nitro group, a cyano group and a heterocyclic group, with CHR.sub.1 R.sub.2, CHR.sub.3 R.sub.4 or CHR.sub.5 R.sub.

Abstract: Novel peptide analogues which exhibit inhibitory activity against aspartic proteinases, a novel species of actinomycetous microorganism which produces said novel peptide analogues, a process for producing said novel analogues by culturing said species and a pharmaceutical composition containing said analogues.

Abstract: A novel N-substituted peptidyl compound represented by the general formula (1): ##STR1## where R.sub.1 is a straight-chained or branched acyl group having 2-10 carbon atoms, a branched, cyclic or partly branched cyclic alkyloxycarbonyl group having 4-15 carbon atoms, a substituted or unsubstituted benzyloxycarbonyl group, a 2,2,2-trichloroethyloxycarbonyl group, a 2-(trimethylsilyl)ethyloxycarbonyl group, a p-toluensulfonyl group, an o-nitrophenylsulfenyl group, a diphenylphosphonothioyl group, a triphenylmethyl group, a 2-benzoyl-1-methylvinyl group or a 4-phenylbutyryl group; R.sub.2 is a hydrogen atom or when taken together with R.sub.1, may form a phthaloyl group; R.sub.3 is an isobutyl group, a n-butyl group or an isopropyl group; R.sub.4 is a butyl group, a benzyl group or a methylthioethyl group; and R.sub.5 is a hydrogen atom or a chloromethyl group, which inhibits the activity of cysteine proteinases.